Introduction {#s1}
============

Human cytomegalovirus (HCMV), a member of the β-herpes virus family, is a highly prevalent pathogen that induces life-long infections notably through the establishment of latency in hematopoietic stem cells (HSC) ([@bib49]). Bouts of reactivation are normally asymptomatic because rapidly controlled by the immune system, but can be fatal in immuno-compromised individuals such as AIDS patients and transplant recipients, in particular when grafts from HCMV-positive donors are given to HCMV-negative individuals ([@bib51]). Furthermore, primary HCMV infection during pregnancy is a leading cause of congenital malformations of the central nervous system ([@bib8]).

The approximately 250 kb genome of HCMV encodes several hundred proteins, some 14 miRNAs and a few long-noncoding RNAs ([@bib52]). Infection of permissive targets such as epithelial cells or fibroblasts leads to a lytic cycle, with a highly orderly transcriptional cascade that first expresses the viral immediate early (IE) genes, the products of which set the cellular stage for the virus and activate the viral early (E) genes. These yield the effectors of viral genome replication, before proteins encoded by the viral late (L) genes finally trigger the formation of new particles. In contrast, when HCMV infects a HSC, the expression of lytic genes is rapidly suppressed and only a few latency-associated transcripts are detected ([@bib19]). The viral genome is then maintained as a stable episome, without replicating or producing new virions ([@bib17]). When HCMV-infected HSC are differentiated in vitro into dendritic cells (DCs) and these are induced to mature, the virus resumes a lytic cycle. Accordingly, blood CD14^+^ monocytes, which are circulating precursors of DCs, harbor latent HCMV.

HCMV reactivation is thus tightly coupled with myeloid differentiation. However, the molecular mechanisms of its persistence in latently infected cells are incompletely understood, albeit known to be associated with epigenetic modifications of the viral chromatin ([@bib2]; [@bib57]; [@bib32]; [@bib36]). In latently infected CD34^+^ HSC or circulating monocytes isolated from seropositive individuals, chromatin at the major immediate early promoter (MIEP) bears histone 3 trimethylated on lysine 9 (H3K9me3), a repressive mark, and heterochromatin protein 1 (HP1) ([@bib50]; [@bib39]). Upon differentiation of latently infected precursors into dendritic cells, H3K9me3 is replaced by high levels of histone acetylation, HP1 is lost, and a lytic cycle is triggered ([@bib53]; [@bib33]; [@bib21]; [@bib40]).

KAP1 (KRAB-associated protein 1), also known as TRIM28 (tripartite motif protein 28) or TIF1β (transcription intermediary factor 1 beta) is a transcriptional co-repressor essential for the early embryonic silencing of endogenous retroelements ([@bib42]; [@bib10]; [@bib56]) and involved in regulating multiple aspects of mammalian homeostasis, including in the hematopoietic system ([@bib25]; [@bib7]; [@bib12]; [@bib45], [@bib46]; [@bib6]). KAP1 binds to the Krüppel-associated box (KRAB) domain present at the N-terminus of KRAB-containing zinc finger proteins (KRAB-ZFPs) ([@bib15]). These constitute the single largest family of transcriptional repressors encoded by the genomes of higher organisms, with close to four-hundred members in either human or mouse, and are endowed with sequence-specific DNA binding ability via a C-terminal array of zinc fingers ([@bib58]). KAP1 harbors from its N- to its C-terminus a RING finger, B-boxes, a coiled-coil region, a HP1-binding motif, a PHD finger and a bromodomain ([@bib24]). The first three of these motifs define the so-called RBCC or TRIM (tripartite motif) region, which is both necessary and sufficient for homo-oligomerization and direct binding to KRAB. The C-terminal effector end of the protein recognizes the backbone of histone tails, and interacts with two histone-modifying enzymes: Mi2α, an isoform of the Mi2 protein found in the NuRD (nucleosome remodeling and histone deacetylation) complex ([@bib47]), and SETDB1 (SET domain, bifurcated 1), an H3K9me3-specific histone methyltransferase ([@bib48]). The H3K9me3 mark in turn creates high affinity genomic binding sites for HP1, bringing more KAP1 complex, which likely explains that KAP1-induced heterochromatin formation can spread several tens of kilobases away from an initial KAP1 docking site ([@bib20]). SETDB1 recruitment is stimulated by sumoylation of the KAP1 bromodomain, the last step of which is mediated intra-molecularly by an E3 ligase activity contained in the PHD domain ([@bib23]). Within the context of DNA damage, the ATM (ataxia telangiectasia mutated) kinase phosphorylates KAP1 at position 824, resulting in decreased KAP1 sumoylation and SETDB1 recruitment, with secondary loss of KAP1 repressor activity ([@bib60], [@bib61]; [@bib35]).

Histone 3 lysine 9 trimethylation and HP1 recruitment are thus signatures of KAP1 action. Furthermore, we previously demonstrated that KRAB/KAP-mediated repression is functional within the context of episomal DNA ([@bib4]). Finally, the KRAB/KAP pathway has been found to influence the replication of two members of the herpes virus family, Epstein--Barr virus (EBV) ([@bib31]) and Kaposi\'s sarcoma-associated herpes virus (KSHV) ([@bib11]; [@bib9]). Based on these premises, we investigated a possible role for KAP1 in the control of HCMV latency. We found that KAP1 is a key mediator of this process, and that it is targeted by an mTOR-mediated phosphorylation switch that can be exploited to force the virus out of latency. Our results suggest new avenues not only for controlling HCMV infection but also for purging the virus from organ transplants.

Results {#s2}
=======

KAP1 is necessary for both establishment and maintenance of HCMV latency in HSC {#s2-1}
-------------------------------------------------------------------------------

We first infected either MRC5 fibroblasts or cord blood-derived CD34^+^ cells with the TB40-E HCMV clinical strain. Monitoring the levels of viral DNA and various RNA transcripts during the following days confirmed that lytic replication occurred in MRC5 cells, known to be fully permissive, whereas latency was established in HSC after an initial outburst of viral gene expression ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}), as previously reported ([@bib18]). To examine the possible impact of KAP1 on this process, we depleted the corepressor by lentivector-mediated RNA interference, complementing *Kap1* knockdown cells by transduction with a vector expressing an shRNA-resistant *Kap1* allele when relevant. We then infected these cells with TB40-E HCMV. In MRC5 cells, where KAP1 depletion was around 98% ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), levels of viral transcripts indicative of a lytic cycle (the IE genes UL123, UL122, the E gene UL54 and the L gene UL94) were comparable in control and KAP1-depleted cells ([Figure 1A](#fig1){ref-type="fig"}) and production of viral proteins IE1 and IE2 was unchanged ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), indicating that the regulator is not essential for productive HCMV replication. In unsorted population of HSC exposed to the knockdown lentivector, KAP1 reduction was only 85% but in sorted CD34^+^ GFP-positive, that is, transduced cells, it reached 95% ([Figure 1---figure supplement 2C,D](#fig1s2){ref-type="fig"}). In this KAP1-depleted subpopulation, expression of immediate early, early and late viral genes at 7 days post-infection was increased between 10- and 35-fold compared with control cells ([Figure 1B](#fig1){ref-type="fig"}), and massive amounts of infectious HCMV particles were released in the supernatant ([Figure 1C](#fig1){ref-type="fig"}). Furthermore, complementation of KAP1-depleted cells with an shRNA-resistant *Kap1* allele restored HCMV latency ([Figure 1---figure supplement 2E--I](#fig1s2){ref-type="fig"}). These results thus indicated that KAP1 is necessary for the establishment of HCMV latency in HSC. We then inverted the sequence of our manipulations to induce *Kap1* knockdown in CD34^+^ cells that had been infected 7 days earlier with the TB40-E virus ([Figure 1---figure supplement 2J](#fig1s2){ref-type="fig"}). 7 days after transduction, we measured the expression of the UL122, UL123, UL54 and UL94 mRNAs, which are found only during a lytic cycle ([@bib39]) ([Figure 1D](#fig1){ref-type="fig"}). All transcripts were significantly upregulated in knockdown cells, which accordingly released infectious viral particles ([Figure 1E](#fig1){ref-type="fig"}). Furthermore, the NF-κB activator TNFα increased viral gene expression and virion production from *Kap1* knockdown but not from control TB40-E-infected CD34^+^ cells ([Figure 1D,E](#fig1){ref-type="fig"}). These data indicate that (i) KAP1 is necessary both for the establishment and for the maintenance of HCMV latency in human HSC, and (ii) the relief of KAP1-mediated repression is not in itself sufficient for full HCMV reactivation in CD34^+^ cells, but provides the ground for stimulation of viral gene expression by HCMV activators such as NF-κB.10.7554/eLife.06068.003Figure 1.KAP1 is required for HCMV latency.RT-qPCR analysis of indicated HCMV genes expression in MRC-5 (**A**) or cord blood CD34^+^ (**B**, **C**, **D**, **E**) cells infected with the TB40-E strain 3 days after (**A**, **B**, **C**) or 7 days prior to (**D**, **E**) being transduced or not (NT) with lentivectors expressing (shKAP1) or not (empty) a small hairpin RNA against *Kap1*, sorting CD34^+^ cells for GFP and CD34 expression. RT-qPCRs were performed 7 days after HCMV infection (**A** and **B**) or 7 days after lentiviral transduction (**D** and **E**). Results are presented as average of fold change expression vs NT after GAPDH and β-2M normalization (n = 4, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). (**C** and **E**) HCMV production in CD34^+^ cells was quantified by plaque assay on MRC-5 cells. Results are presented as average of PFU/ml (n = 3, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, error bars as s.d.). See [Figure 1---figure supplements 3, 4](#fig1s3 fig1s4){ref-type="fig"} for all individual experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.003](10.7554/eLife.06068.003)10.7554/eLife.06068.004Figure 1---figure supplement 1.KAP1 is necessary for both establishment and maintenance of HCMV latency in HSC.HCMV kinetics analysis performed on MRC-5 fibroblasts (**A**) or CD34^+^ HSC (**B**). HCMV mRNA and DNA expression were quantified at day 1-3-5-7 and 10 post-infection by RT-qPCR.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.004](10.7554/eLife.06068.004)10.7554/eLife.06068.005Figure 1---figure supplement 2.KAP1 is necessary for both establishment and maintenance of HCMV latency in HSC.KAP1 knockdown and re-complementation efficiency were tested by RT-qPCR (**A**, **C**, **E**, **J**) and Western-blot analysis (**D**). MRC-5 fibroblasts (**A** and **B**) or CD34^+^ cells (**C**--**J**) were transduced or not (NT) with lentiviral vectors expressing (shKAP1) or not (empty, scramble) an shRNA against *Kap1*, and co-transduced with a vector expressing (KAP1-optim) or not (control) an shRNA-resistant *Kap1* allele, 3 days before (**A**--**H**) or 7 days after (**J**) infection with the TB40-E HCMV strain. Indicated HCMV transcripts were quantified by RT-qPCR for CD34^+^ cells (**F**--**I**) and by western blot analysis for MRC-5 (**B**). All results are presented as average of fold change expression vs NT after GAPDH and β-2M normalization for mRNA and GAPDH and Albumin for DNA (n = 4, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). Western-Blots are representative of three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.005](10.7554/eLife.06068.005)10.7554/eLife.06068.006Figure 1---figure supplement 3.KAP1 is necessary for establishment of HCMV latency in HSC.[Figure 1A,B,C](#fig1){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.006](10.7554/eLife.06068.006)10.7554/eLife.06068.007Figure 1---figure supplement 4.KAP1 is necessary for maintenance of HCMV latency in HSC.[Figure 1D,E](#fig1){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.007](10.7554/eLife.06068.007)

HCMV latency in HSC correlates with KAP1-mediated recruitment of SETDB1 and HP1α and with H3K9 trimethylation {#s2-2}
-------------------------------------------------------------------------------------------------------------

Cells in which HCMV expression was induced following KAP1 depletion kept expressing the CD34 stem cell marker, indicating that viral activation was not simply due to their differentiation into normally permissive cells such as activated DCs or macrophages. Still, as KAP1 exerts pleomorphic effect on hematopoiesis ([@bib6]), we could not exclude that its depletion induced HCMV lytic genes expression through indirect effects. We thus asked whether the co-repressor associates with the HCMV genome by performing KAP1-specific chromatin immunoprecipitation-deep sequencing (ChIP-seq) analyses on material isolated from human CD34^+^ HSC at 7 days post-TB40-E infection. Using a stringent peak-calling algorithm and validating its results by ChIP-PCR, we identified 28 major KAP1-enriched regions on the HCMV genome ([Figure 2A,B](#fig2){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Supporting the functional significance of KAP1 recruitment to latent HCMV genomes, ChIP-PCR analyses also detected SETDB1, H3K9me3 and HP1α at these KAP1-enriched regions ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Furthermore, in line with our former demonstration that heterochromatin formation can spread several tens of kilobases away from primary KAP1 docking sites ([@bib20]), H3K9me3 and HP1α were found at significant distances from these major KAP1 peaks, and particularly covered the major immediate early promoter (MIEP), the viral origin of lytic replication (OriLyt) and the UL112 gene. In contrast, the repressive mark was not found at genes known to be expressed during latency such as UL138 or LUNA ([@bib39]) ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Importantly, SETDB1 and HP1α recruitment as well as H3K9 trimethylation were lost when KAP1 was depleted by RNA interference prior to HSC infection, supporting a model whereby the corepressor recruits these heterochromatin-inducing factors ([Figure 2---figure supplement 1A--D](#fig2s1){ref-type="fig"}).10.7554/eLife.06068.008Figure 2.KAP1, SetDB1 and H3K9Me3 are enriched on the HCMV genome in latently infected HSC.(**A**) KAP1 binding sites on HCMV genome in TB40-E-infected CD34^+^ cells, mapped by ChIP-Seq performed at day 7 post-infection. Results are presented as hit point upper 120 on the reference sequence GenBank EF999921.1, indicating all KAP1 peaks (1--28). (**B** and **C**) ChIP-PCR with anti-KAP1 (**B**), anti-SetDB1 and anti-H3K9Me3 (**C**) antibodies were performed on ChIP-Seq-mapped KAP1 peaks (1--28) plus two KAP1-negative HCMV regions (Neg 1 and 2), using EVX-1 and GAPDH as negative cellular gene controls, and ZNF180 and RP11-517P14.7 as positive controls. (**D**) H3K9me3-specific ChIP-PCR of two latency genes (UL138, LUNA) and three regions active during lytic replication (OriLyt, UL112 and MIEP), with the same controls as in (**C**). Results are presented as total input fold enrichment (EVX-1 normalized).**DOI:** [http://dx.doi.org/10.7554/eLife.06068.008](10.7554/eLife.06068.008)10.7554/eLife.06068.009Figure 2---figure supplement 1.KAP1-dependent recruitment of HP1α and SETDB1 with H3K9 trimethylation of HCMV genome in latently infected HSC.ChIP-PCR analysis of TB40-E-infected WT MRC-5 (**A** and **B**) KAP1-depleted CD34^+^ (**A**--**D**), WT CD34^+^ (**A** and **B**) or mDC (**A** and **B**) with antibodies against HP1α (**A** and **B**) SETDB1 (**C**) or H3K9me3 (**C** and **D**), as described in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.009](10.7554/eLife.06068.009)

An mTOR-mediated KAP1 phosphorylation switch between HCMV latency and lytic replication {#s2-3}
---------------------------------------------------------------------------------------

We then examined the epigenetic status of HCMV genome when TB40-E-infected CD34^+^ cells were differentiated in mature dendritic cells (mDCs), a procedure previously demonstrated to result in HCMV activation. As expected, the TB40-E DNA was no longer associated with SETDB1 or HP1α and did not bear the H3K9me3 repressive mark in the CD34-derived mDCs ([Figure 3A](#fig3){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). However, KAP1 was surprisingly still associated with the viral genome in these targets ([Figure 3B](#fig3){ref-type="fig"}). The same pattern was recorded in TB40-E infected MRC-5 cells, where the virus achieves a complete lytic cycle ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). It suggested that HCMV reactivation and replication could occur in spite of corepressor binding. To probe this issue further, we infected CD34^+^ cord blood and MRC5 cells with the HCMV AD169 laboratory strain, which is incapable of inducing latency ([@bib18]; [@bib44]). At day 7 post-infection, while the productively transcribed AD169 genome carried as expected neither SETDB1 nor H3K9Me3, it was still bound by KAP1 in both cell types as robustly as the latent TB40-E strain in HSC ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). Therefore, it is not KAP1 recognition but rather the secondary recruitment of its SETDB1 effector and other KAP1-associated heterochromatin inducers such as HP1, which is responsible for HCMV latency.10.7554/eLife.06068.010Figure 3.A KAP1 phosphorylation switch governs HCMV progression from latency to lytic replication.ChIP-PCR of indicated HCMV genomic regions was performed with anti-SetDB1 and anti-H3K9Me3 (**A**), anti-KAP1 (**B**) or anti- S824 phosphoKAP1 antibodies (**C** and **D**) on material extracted from TB40-E-infected cells CD34^+^ cells (**C**) or mature dendritic cells derived therefrom (**A**, **B**, **D**), using same controls as in [Figure 2](#fig2){ref-type="fig"}. Results are presented as total input fold enrichment after EVX-1 normalization.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.010](10.7554/eLife.06068.010)10.7554/eLife.06068.011Figure 3---figure supplement 1.A KAP1 phosphorylation switch distinguishes HCMV latency and lytic replication.ChIP-PCR with SETDB1-, H3K9Me3-, KAP1-, pS^824^KAP1-specific antibodies were performed on MRC-5 fibroblasts (**A**, **B**, **F**, **G**) or CD34^+^ HSC (**C**, **D**, **E**) infected with the HCMV TB40-E (**A**, **B**, **G**) or AD169 (**C**, **D**, **E**, **F**) strains, as described in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.011](10.7554/eLife.06068.011)

Within the context of DNA damage, ATM phosphorylates KAP1 on serine 824, thereby reducing its ability to bind SETDB1 hence its repressor potential ([@bib60], [@bib61]; [@bib35]). We thus asked whether this modification could alter the consequences of KAP1 recruitment to the HCMV genome. We could immunoprecipitate the TB40-E DNA with pS^824^KAP1-specific antibodies in HCMV-reactivated mDC but not in latently infected HSC, with a pattern of genomic recruitment identical to that delineated with the global KAP1 antibody in both cell types ([Figure 3C,D](#fig3){ref-type="fig"}). Furthermore, pS^824^KAP1 was similarly found associated with the replicating AD169 viral DNA in both MRC5 cells and CD34^+^ HSC ([Figure 3---figure supplement 1E,F](#fig3s1){ref-type="fig"}) and with the TB40-E-genome in productively infected MRC-5 fibroblasts ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Confirming these data, immunofluorescence detected the presence of pS^824^KAP1 in 100% of TB40-E- or AD169-infected MRC-5 fibroblasts, but not in uninfected fibroblasts ([Figure 4A,B--D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), nor in CD34^+^ HSC latently infected with the TB40-E strain, which could be identified by their loss of expression of the surface protein MRP1 as recently described ([@bib59]) ([Figure 4E](#fig4){ref-type="fig"}).10.7554/eLife.06068.012Figure 4.mTOR inhibition prevents HCMV-induced KAP1 phosphorylation.MRC-5 (**A**, **B**, **C**) and CD34^+^ (**D** and **E**) cells, infected (AD169 or TB40-E) or not (Non Infected) with HCMV, and treated or not (Non Treated) with mTOR inhibitor (Torin1) were examined by immunofluorescence with anti-IE and anti-MRP1 antibodies (Alex-488, green), and anti-S824 phosphoKAP1 antibodies (Alexa 568, red). DNA was stained with Dapi (blue). White arrows represent latently infected cells (MRP-1 negative cells). Scale Bar in white represents 10 µm for MRC-5 and 5 µm for CD34^+^. All pictures are representative of slide overview from three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.012](10.7554/eLife.06068.012)10.7554/eLife.06068.013Figure 4---figure supplement 1.mTOR and HCMV-associated KAP1 phosphorylation.(**A**--**F**) Confocal microscopy coupled to immunofluorescence was performed on MRC-5 (**A**--**C**) or CD34^+^ (**E** and **F**) HCMV infected (TB40-E, AD169) or not (Non Infected) and treated or not (Non Treated) with mTOR (Rapamycin, Torin1) or ATM (KU55933) inhibitors. Staining was performed with antibodies against IE (Alexa 488, green), and pS^824^KAP1 (Alexa 568, red), staining DNA with Dapi (blue). White scale bar, 10 µm. All pictures are representative of results obtained in three independent experiments. (**D**) KAP1 levels in MRC-5 Treated or not (NT) with Rapamycin (Rapa) Torin-1 (Torin) or KU55933 (KU), analyzed by western-blot. Results are representative of three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.013](10.7554/eLife.06068.013)10.7554/eLife.06068.014Figure 4---figure supplement 2.mTOR and HCMV-associated KAP1 phosphorylation.(**A**--**C**) Confocal microscopy coupled to immunofluorescence was performed on MRC-5 (**A**--**C**), HCMV infected (TB40-E) or not (Non Infected) and treated or not (Non Treated) with mTOR inhibitors (Torin1). Staining was performed with antibodies against IE or anti-β-Tubulin (Alexa 488, green), and pS^473^KAP1 (Alexa 568, red), staining DNA with Dapi (blue). White scale bar, 10 µm. All pictures are representative of results obtained in three independent experiments. (**D**) In vitro phosphorylation of GST-KAP1 by recombinant mTOR, using Western blot and Ponseyu staining to detect pS^824^KAP1 and total KAP1, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.014](10.7554/eLife.06068.014)

We then set to identify the kinase responsible for phosphorylating KAP1 in cells productively infected with HCMV. The ATM inhibitor KU55933 did not prevent this process, suggesting that this known KAP1 kinase did not play a primary role ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). We thus turned to the mammalian target of rapamycin (mTOR), which was previously found activated in cells replicating HCMV ([@bib34]; [@bib14]; [@bib13]; [@bib37]). When TB40-E infected MRC-5 cells were treated with the mTOR inhibitors rapamycin or Torin1 ([@bib54]; [@bib55]), the phosphoKAP1-specific immunofluorescence signal was suppressed ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), whereas total levels of KAP1 were unaffected ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Torin1-preventable pS^824^KAP1 accumulation was also documented in CD34^+^ HSC infected with the replicative AD169 strain ([Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1E,F](#fig4s1){ref-type="fig"}). In this setting, the IE protein-specific signal was reduced by the mTOR inhibitor, consistent with some repression of viral gene expression. Of note, some KAP1 phosphorylated on serine 473 was detected in MRC5 cells, but this was independent of HCMV infection and Torin1-resistant ([Figure 4---figure supplement 2A--C](#fig4s2){ref-type="fig"}). In contrast, recombinant mTOR could phosphorylate GST-KAP1 on S^824^ in vitro ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}).

Cell fractionation analyses indicated that pS^824^KAP1 accumulated in the nucleus of CMV-infected cells, which also displayed increased levels of phospho-S6 ribosomal protein, a marker of mTOR activation ([Figure 5A](#fig5){ref-type="fig"}). Indirect immunofluorescence and confocal microscopy further revealed mTOR-specific foci in the nucleus of TB40- or AD169-infected but not control MRC5 cells ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Finally, ChIP with an mTOR-specific antibody demonstrated that the kinase associated with the CMV genome at the same places regions as pS^824^KAP1 ([Figure 5C](#fig5){ref-type="fig"}). Consistent with a restriction of KAP1 phosphorylation and inactivation to CMV-associated molecules, the corepressor could still mediate the transcriptional silencing of an integrated TetO-PGK-GFP cassette via a Tet repressor-KRAB fusion protein ([@bib62]) in virus-infected cells ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).10.7554/eLife.06068.015Figure 5.mTOR associates with the HCMV genome during lytic replication.(**A**) MRC-5 cells were infected 3 days (TB40-E) or not (NT) with HCMV and harvested for cell fractionation. IE1/2, α-Tubulin, KAP1, KAP1 pS824, Histone 3 and phosphorylated or not S6 ribosomal protein expression/localization in Total extract, cytosolic (soluble) nuclear (insoluble) and chromatin (chromatin) parts were analysed by Western-Blot. (**B**) Immunofluorescence by confocal microscopy was performed on MRC-5, HCMV infected (TB40-E, AD169) or not (Non Infected). Staining was performed with anti-IE (Alex-488, green), and anti-mTOR antibodies (Alexa 568, red). DNA was stained with Dapi (blue). Scale Bar in white represents 5 µm. (**C**) ChIP-PCR for indicated HCMV genomic regions were performed with anti-mTOR or control-IgG on material extracted from TB40-E-infected MRC-5. Results are presented as total input fold enrichment after HCMV Neg1 region normalization.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.015](10.7554/eLife.06068.015)10.7554/eLife.06068.016Figure 5---figure supplement 1.mTOR nuclear translocation and KAP1 activity in HCMV replicating cells.(**A**) Confocal microscopy coupled to immunofluorescence was performed on MRC-5, infected (TB40-E, AD169) or not (Non Infected) with HCMV, using antibodies against IE- (Alex-488, green) or mTOR (Alexa 568, red), staining DNA with Dapi (blue). White scale bar, 10 µm. (**B**) MRC-5 cells were transduced with a lentiviral vector expressing GFP from the TetO-PGK promoter (TetO-GFP) with or without tTR-KRAB, infected or not with HCMV and treated or not with DOX as indicated. Results are presented as % of GFP positive cells, using non-infected and Dox treated cells as a 100% reference. (n = 3, \*\*p \< 0.01, error bars as s.d.).**DOI:** [http://dx.doi.org/10.7554/eLife.06068.016](10.7554/eLife.06068.016)

Forcing HCMV out of latency by pharmacological manipulation of KAP1 {#s2-4}
-------------------------------------------------------------------

These results suggested that HCMV silencing might be amenable to suppression by pharmacologically induced KAP1 phosphorylation. In the absence of strictly specific mTOR activator, we turned to ATM, a kinase previously demonstrated as capable of phosphorylating KAP1 on S^824^ ([@bib61]). When HSC infected 5 days earlier with TB40-E were incubated with the ATM activator chloroquine ([@bib3]), intracellular levels of viral RNAs and DNA increased ([Figure 6A,B](#fig6){ref-type="fig"}), and infectious viral particles were released in the supernatant ([Figure 6C](#fig6){ref-type="fig"}). Supporting the specificity of the observed phenomenon, Torin-1 did not block chloroquine-induced HCMV RNA, DNA and viral particle production, whereas the ATM inhibitor Ku55933 prevented this process ([Figure 6](#fig6){ref-type="fig"}). These results obtained in a first set of HSC obtained from three donors were confirmed in another group of three donors, where it was further observed that levels of viral transcripts increased in drug-treated cells only transiently after a single dose of drug but steadily if three doses were administered over 5 days ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), and that single doses of the ATM activator prevented the progressive drop in viral DNA that was observed in control cells, while repeated doses triggered an augmentation in viral DNA copies, indicative of genome replication ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Correlating these quantitative virological data, chloroquine treatment allowed the detection by immunofluorescence of pS^824^KAP1-positive cells ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). These were also systematically positive for IE antigens ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), confirming that the virus harbored by these cells had exited latency. Finally, when the supernatant of TB40-E-infected HSC exposed to chloroquine was used to inoculate MRC5 fibroblasts, it induced the accumulation of viral DNA in these targets ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), demonstrating that the production of replication-competent virus had been induced by ATM-activating treatment of the latently infected HSC. Noteworthy, pS^824^KAP1 was detected only in HCMV IE-positive cells, which strongly suggests that KAP1 became phosphorylated in these cells through the combined action of ATM and some HCMV-encoded factor. Importantly, these effects were induced without drop in KAP1 levels or loss of surface expression of the CD34 stem cell marker ([Figure 6---figure supplement 2A,B](#fig6s2){ref-type="fig"}). Additional evidence strongly suggested that chloroquine stimulated HCMV via KAP1 phosphorylation. First, the drug did not further boost TB40-E in MRC-5 cells, where viral replication is KAP1-insensitive ([Figure 6---figure supplement 2C,D](#fig6s2){ref-type="fig"}). Second, it did not further stimulate HCMV gene expression and virion release in CD34^+^ cells depleted for KAP1, whether or not these were complemented with a phosphorylation resistant S^824^A KAP1 mutant ([Figure 6---figure supplement 3A,B](#fig6s3){ref-type="fig"} and [Figure 6---figure supplement 4AB](#fig6s4){ref-type="fig"}). Third, and by contrast, chloroquine did reactivate HCMV when these knockdown cells were complemented with wild-type KAP1 ([Figure 6---figure supplement 4A,B](#fig6s4){ref-type="fig"}).10.7554/eLife.06068.017Figure 6.Forcing HCMV out of latency in CD34^+^ cells by KAP1 pharmacological manipulation.After 5 days of infection with TB40-E, CD34^+^ cells were treated three times (Day 0, 3 and 5) or not (NT) with Chloroquine (Chloro) alone or in combination with the mTor inhibitor Torin-1 (Torin) or the ATM inhibitor KU59933 (KU). (**A**) Indicated HCMV transcripts were quantified by RT-qPCR, using GAPDH and β-2 microglobulin for normalization. (**B**) HCMV DNA associated with the TB40-E-infected HSC was quantified by qPCR, normalizing with the GAPDH and albumin genes. Data are presented as average of three different experiments performed with cells from independent donors. (**C**) Supernatant from the TB40-E-infected CD34^+^ cells, harvested after 7 days of treatment and the viral production was quantified by classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram represents an average of three different experiments performed with HSC from three independent donors (n = 3, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). See [Figure 6---figure supplements 5, 6](#fig6s5 fig6s6){ref-type="fig"} for all individual experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.017](10.7554/eLife.06068.017)10.7554/eLife.06068.018Figure 6---figure supplement 1.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.After 5 days of infection with TB40-E, CD34^+^ cells were treated or not (mock) with chloroquine in single or multiple doses as indicated. Indicated HCMV transcripts were quantified by RT-qPCR, using GAPDH and β-2 Microglobulin for normalization (**A**). HCMV DNA associated with the TB40-E-infected HSC was quantified by qPCR, normalizing with the GAPDH and albumin genes (**B**). Data are presented as average of three different experiments performed with cells from independent donors. (**C**) Immuno-fluorescent staining was performed on CD34^+^ cells for pS^824^KAP1 (pS824), HCMV IE1-2 (IE), or total KAP1 (KAP1), using Dapi for DNA. White scale bar, 10 µm. All pictures are representative of three independent experiments. (**D**) Supernatant from the TB40-E-infected CD34^+^ cells, harvested after 7 days of treatment, was used to infect MRC-5 fibroblasts, which were assessed for their viral DNA content 2 and 7 days later by qPCR. Results are presented as HCMV DNA level normalized for GAPDH and Albumin. Histogram represents an average of three different experiments performed with HSC from three independent donors (n = 3, \*p \< 0.05, error bars as s.d.).**DOI:** [http://dx.doi.org/10.7554/eLife.06068.018](10.7554/eLife.06068.018)10.7554/eLife.06068.019Figure 6---figure supplement 2.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.(**A**) Immuno-fluorescent staining was performed on CD34^+^ cells for total KAP1 (KAP1), using Dapi for DNA. White scale bar, 10 µm. All pictures are representative of three independent experiments. (**B**) Percentage of CD34^+^ cells after 7 days of treatment was quantified by FACS with a PE-anti-CD34 antibody. Results are presented of fold change expression vs NT of three independent experiments. HCMV DNA (**C**) and mRNAs (**D**) were quantified by qPCR in MRC-5 cells infected for 5 days with TB40-E in the presence or absence of chloroquine. Results are presented as HCMV DNA or mRNA levels normalized for GAPDH and Albumin for DNA, GAPDH and β-2M for mRNA.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.019](10.7554/eLife.06068.019)10.7554/eLife.06068.020Figure 6---figure supplement 3.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.(**A**) RT-qPCR analysis of indicated HCMV transcripts in cord blood CD34^+^ cells infected with the TB40-E strain 7 days prior to being transduced or not (NT) with lentivectors expressing (shKAP1) or not (empty) a small hairpin RNA against *Kap1*. RT-qPCRs were performed 7 days after lentiviral transduction treated or not (NT) with chloroquine as described in [Figure 6](#fig6){ref-type="fig"}. Results are presented as average of fold change expression vs NT after GAPDH and β-2M normalization (n = 4, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). (**B**) HCMV production in CD34^+^ cells was quantified by plaque assay on MRC-5 cells. Results are presented as average of PFU/ml (n = 3, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.).**DOI:** [http://dx.doi.org/10.7554/eLife.06068.020](10.7554/eLife.06068.020)10.7554/eLife.06068.021Figure 6---figure supplement 4.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.(**A**) RT-qPCR analysis of indicated HCMV transcripts in CD34^+^ cells infected with the TB40-E strain, 3 days after transduction or not (NT) with lentiviral vectors expressing or not (empty) an shRNA (shKAP1) against *Kap1*, together with a vector expressing an shRNA-resistant allele of the S^824^ KAP1 phospho-resistant mutant (S824A) or a wild type KAP1 (KAP1.opt) lentiviral vector. After 5 days of infection with TB40-E, CD34^+^ cells were treated three times (Day 0, 3 and 5) or not (NT) with Chloroquine (Chloro). Indicated HCMV transcripts were quantified by RT-qPCR, using GAPDH and β-2 microglobulin for normalization. (**B**) Supernatant from the TB40-E-infected CD34^+^ cells, harvested after 7 days of treatment and the viral production was quantified by classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram represents an average of three different experiments performed with HSC from three independent donors (n = 3, \*\*p \< 0.01, error bars as s.d.).**DOI:** [http://dx.doi.org/10.7554/eLife.06068.021](10.7554/eLife.06068.021)10.7554/eLife.06068.022Figure 6---figure supplement 5.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.[Figure 6A](#fig6){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.022](10.7554/eLife.06068.022)10.7554/eLife.06068.023Figure 6---figure supplement 6.HCMV can be forced out of latency in CD34^+^ cells by pharmacological manipulation.[Figure 6B,C](#fig6){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.023](10.7554/eLife.06068.023)

We also asked whether the pharmacological induction of KAP1 phosphorylation could trigger HCMV production from circulating monocytes. Monocytes were purified from the peripheral blood of seropositive individuals and exposed to three doses (at days 0, 3 and 5) of chloroquine, alone or in combination with Torin-1 or KU55933 ([Figure 7](#fig7){ref-type="fig"}). ATM activation did not trigger the differentiation of the monocytes into dendritic cells or macrophages, as verified by measuring the cell surface expression of CD1a, CD14, CD80 and CD86 ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). However, it induced the intracellular accumulation of HCMV DNA and the release of infectious viral particles from these monocyte populations. Furthermore, Ku55933 but not Torin-1 prevented the stimulating effect of chloroquine, as noted in HSC.10.7554/eLife.06068.024Figure 7.Inducing KAP1 phosphorylation releases HCMV from latency in monocytes.Monocytes from HCMV seropositive donors were purified and treated three times (Day 0, 3 and 5) or not (NT) with Chloroquine (Chloro) alone in combination with Torin-1 (Torin) or KU59933. (**A**) HCMV DNA associated with the monocytes was quantified by qPCR, normalizing with the GAPDH and albumin genes. Data are presented as average of three different experiments performed with cells from independent donors. (**B**) Supernatant from the monocytes, harvested after 7 days of treatment and the viral production was quantified by classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram represents an average of three different experiments performed with HSC from three independent donors (n = 3, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). See [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"} for all individual experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.024](10.7554/eLife.06068.024)10.7554/eLife.06068.025Figure 7---figure supplement 1.Monocytes do not differentiate during pharmacological reactivation of HCMV.After 7 days of treatment with chloroquine, monocytes were examined by FACS for the surface expression of CD1a, CD14, CD80 and CD86, analyzing results with the FlowJo software. Graphs are representative of experiments performed with cells from three different HCMV-seropositive donors.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.025](10.7554/eLife.06068.025)10.7554/eLife.06068.026Figure 7---figure supplement 2.Monocytes do not differentiate during pharmacological reactivation of HCMV.[Figure 7](#fig7){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.026](10.7554/eLife.06068.026)

These data demonstrate that inducing KAP1 phosphorylation results in releasing HCMV from its latent state by relieving repressive marks on the viral chromatin. Nevertheless, levels of viral gene expression achieved in this setting remain lower than observed when HCMV-harboring precursors are differentiated into macrophages or mature dendritic cells, where NF-κB has been demonstrated to drive viral transcription. We thus exposed latently infected CD34^+^ cells to chloroquine and TNF- α (5 ng/ml), either alone or in combination ([Figure 8](#fig8){ref-type="fig"}). With TNF alone, HCMV transcription was not induced, indicating that the virus remained latent. With chloroquine alone, significant induction of cell-associated viral transcripts (approx. 100-fold) and DNA (approx. fivefold) was measured, and viral particles were released in the supernatant (10,000 PFU/ml in the experiment depicted in [Figure 8](#fig8){ref-type="fig"}). With the further addition of TNF, levels of CMV-specific RNAs increased by another 10-fold, the amounts of cell-associated viral DNA doubled, and virion production was boosted by a factor 10. Importantly, this dual treatment did not trigger the differentiation of the HSC ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Taken together, these results suggest a model whereby chloroquine treatment renders the HCMV chromatin permissive for transcription through KAP1 S^824^ phosphorylation, which then allows TNF to induce full viral gene expression via NF-kB activation.10.7554/eLife.06068.027Figure 8.Combining KAP1 phosphorylation and NF-κB induction increases HCMV activation from latently infected HSC.After 5 days of infection with TB40-E, CD34^+^ cells were treated three times (Day 0, 3 and 5) or not (NT) with chloroquine (Chloro) in combination or not with 5 ng/ml of recombinant TNF-α (TNF). (**A**) Indicated HCMV transcripts were quantified by RT-qPCR, using GAPDH and β-2 microglobulin for normalization. (**B**) HCMV DNA associated with the TB40-E-infected HSC was quantified by qPCR, normalizing with the GAPDH and albumin genes. Data are presented as average of three different experiments performed with cells from independent donors. (**C**) Supernatant from the TB40-E-infected CD34^+^ cells, harvested after 7 days of treatment and the viral production was quantified by classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram represents an average of three different experiments performed with HSC from three independent donors (n = 3, \*p \< 0.05, \*\*p \< 0.01, error bars as s.d.). See [Figure 8---figure supplements 2, 3](#fig8s2 fig8s3){ref-type="fig"} for all individual experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.027](10.7554/eLife.06068.027)10.7554/eLife.06068.028Figure 8---figure supplement 1.Pharmacological activation of HCMV does not trigger CD34^+^ cells differentiation.After 7 days of treatment with chloroquine and TNF-α, cells were analyzed by FACS for CD34 surface expression. Representative of experiments performed on cells from three different donors.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.028](10.7554/eLife.06068.028)10.7554/eLife.06068.029Figure 8---figure supplement 2.Pharmacological activation of HCMV does not trigger CD34^+^ cells differentiation.[Figure 8A](#fig8){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.029](10.7554/eLife.06068.029)10.7554/eLife.06068.030Figure 8---figure supplement 3.Pharmacological activation of HCMV does not trigger CD34^+^ cells differentiation.[Figure 8B,C](#fig8){ref-type="fig"} source datas.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.030](10.7554/eLife.06068.030)

Discussion {#s3}
==========

This work sheds light on the mechanisms of HCMV persistence by revealing that, in latently infected hematopoietic stem cells, the master co-repressor KAP1 recruits HP1α and SETDB1 to the viral genome, triggering H3K9 methylation and heterochromatin formation. Our results correlate with the observation that, in latently infected CD34^+^ HSC or circulating monocytes isolated from seropositive individuals, chromatin at the HCMV MIEP bears H3K9me3 and HP1 ([@bib50]). Our finding that KAP1 partakes in both the establishment and the maintenance of HCMV latency also corroborates the previously noted absence of more permanent silencing marks, such as DNA methylation, on latent HCMV genomes ([@bib22]). We provide another important clue to the understanding of HCMV biology by revealing that the virus exits latency when KAP1 becomes phosphorylated on serine 824, which blocks its ability to recruit SETDB1 hence abrogates its co-repressor potential. We further identify mTOR as responsible for this KAP1 phosphorylation switch, and capitalizing on these findings we finally demonstrate that HCMV can be forced out of latency by pharmacological activation of ATM, another KAP1 kinase, and that this effect can be potentiated by adding TNF, an inducer of NF-kB. Whether KAP1 phosphorylation relieves HCMV from latency only by dislodging SETDB1 and HP1 from the viral chromatin or through more active mechanisms remains to be determined. Interestingly, a small molecule inhibitor of LSD1/KDM1A was recently found to decrease HCMV immediate early gene transcription ([@bib30]). It could be that pS^824^KAP1 plays a role in attracting this H3K9 demethylase to the viral genome.

There are remarkable analogies but also interesting differences between our results and recent data implicating KAP1 in the control of KSHV latency ([@bib11]; [@bib9]). In cells harboring latent KSHV genomes, KAP1, HP1 and H3K9me3 were enriched at more than two thirds of viral promoters, and KAP1 knockdown reduced these repressive marks and stimulated virus production. Furthermore, upon induction of a lytic cycle by overexpression of the Rta viral transactivator, KAP1 dissociated from the viral genome, resulting in loss of HP1 and H3K9me3. This correlated with phosphorylation of KAP1 on S^824^, apparently mediated by the viral kinase vPK, with reciprocal decrease in the level of KAP1 sumoylation ([@bib11]). Here, while we find that a KAP1 phosphorylation switch can also force HCMV out of latency, we demonstrate that, with this virus, the phosphorylated form of the master repressor remains associated with actively transcribed viral genomes. Furthermore, we implicate the cellular kinase mTOR in KAP1 phosphorylation. It was previously noted that both the mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2) arms of the mTOR pathway are activated during lytic HCMV replication ([@bib26], [@bib27], [@bib28]). This results in phosphorylating notably the eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) and the p70S6 kinase (S6K), which enhances viral protein translation and more generally minimizes cellular stress responses ([@bib14]; [@bib37]). Here, we identify KAP1 as another substrate of this cascade, by observing that (i) the co-repressor is phosphorylated on serine 824 in cells productively infected with HCMV; (ii) this process is inhibited by the mTOR inhibitors rapamycin and Torin1; and (iii) mTOR targets the viral chromatin at KAP1-bearing genomic sites during a lytic cycle. Conversely, we could force HCMV out of transcriptional dormancy by inducing the activation of ATM, another kinase targeting KAP1 on serine 824, in latently infected HSC and circulating monocytes. Nevertheless, our data also point to the role of viral factors in targeting this process. First, S^824^ phosphoKAP1 was detected only in HCMV IE antigen-positive cells. Second, KAP1 conserved its ability to repress a chromosomal target in cells where its HCMV silencing activity was abrogated by phosphorylation. This strongly suggests that mTOR is targeted to the HCMV genome, where the viral DNA-associated KAP1 molecules are then exposed to its action, a model supported by the results of our mTOR-specific chromatin immunoprecipitation. Such spatial compartmentalization would not be unprecedented, as site-specific KAP1 phosphorylation is also observed in case of DNA damage ([@bib60]), and as mTOR has itself been observed to be directed to sites of HCMV assembly ([@bib13]). More generally, it will be interesting to ask whether the KRAB/KAP1 pathway contributes to the latency of other herpes viruses, even though in the case of EBV the only evidence available so far is that it instead promotes viral DNA replication ([@bib31]).

Latency is a dominant, cell type- and differentiation stage-specific mechanism ([@bib44]; [@bib19]), as it is limited to HSC and cells of the myeloid lineage such as monocytes, and to HCMV clinical isolates (e.g., TB40-E) that contain genomic regions commonly deleted in latency-incompetent laboratory strains (e.g., AD169) ([@bib18]; [@bib38]; [@bib36]). Our findings thus suggest that, in HSC, a latency-specific gene product counters HCMV-induced mTOR-mediated KAP1 phosphorylation, for instance by either blocking the kinase or by acting as or inducing a KAP1-specific phosphatase. This warrants investigations aimed at elucidating this aspect, and at determining whether, when and, if so, downstream of what pathway mTOR becomes activated and KAP1 phosphorylated during the differentiation of HSC towards macrophages or activated DCs, the cells in which HCMV transcription becomes fully productive.

KAP1 is not a DNA-binding protein, and is classically tethered to given genomic loci, for instance endogenous retroelements, by sequence-specific KRAB-ZFPs ([@bib15]; [@bib63]; [@bib41]; [@bib10]). By analogy, it is tempting to hypothesize that members of the KRAB-ZFP family are also involved in recognizing the HCMV DNA. In support of this model, KAP1 recruitment to the HCMV genome was lost when the KRAB-binding RBCC domain was deleted (not illustrated). Since we detected close to thirty major KAP1 peaks on the HCMV DNA and failed to identify a common motif amongst all these sequences, more than one DNA-binding protein, whether or not KRAB-ZFP, is likely involved in docking the corepressor at these sites. In the case of KSHV, the latency protein LANA is responsible for tethering sumoylated KAP1 and the KAP1-bound Sin3A repressor to the Rta promoter, through its ability to interact with SUMO-2-bearing proteins. Upon hypoxia, KAP1 is de-sumoylated and together with Sin3A is released from the KSHV genome, leading to the activation of the LANA-associated HIF-1α, the inducible subunit of the hererodimeric HIF-1 (hypoxia-induced factor 1), thus activating viral gene expression ([@bib9]). By analogy, it could be that a virally encoded product contributes to targeting KAP1 to the HCMV genome.

Our data have important clinical implications. First, it was recently noted that transplant recipients placed on immunosuppressive regimens that included rapamycin were less likely to suffer serious CMV-related complications than patients for whom this drug was omitted ([@bib1]; [@bib43]). The present work indicates that this beneficial effect might stem at least in part from a prevention of viral reactivation. This warrants further studies to assess the positive impact of this and other mTOR inhibitors on the control of HCMV infection, whether after transplantation or in other settings. Of note, a recent study demonstrated that rapamycin did not prevent HCMV reactivation from latently infected dendritic cells in vitro ([@bib16]). However, it could be that KAP1 phosphorylation was already established in this system, and that maturation of the DCs only resulted in activating transcription factors that are strong stimulators of HCMV gene expression, such as NF-κB.

Our discovery that HCMV can be forced out of latency by pharmacological manipulation suggests new avenues to eradicate infection by combining ATM and NF-κB activation with immune- or drug-based approaches aimed at killing HCMV-infected cells. The systemic administration of ATM and NF-κB activators may cause important side effects, and HCMV eradication is anyway probably unnecessary in immuno-competent individuals. However, the ex vivo treatment of HCMV-positive transplants, for instance bone marrow or HSC purified therefrom, could be readily envisioned to purge latently infected cells prior to engraftment, notably in the high-risk setting of HCMV-negative recipients.

Materials and methods {#s4}
=====================

Cell culture and treatments {#s4-1}
---------------------------

CD34^+^ cells from HCMV negative human cord blood were obtained from the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois, CHUV, Switzerland) delivery room with proper informed consent, layered on Ficoll gradient, purified with the CD34^+^ cell separation kit (Miltenyi Biotec, Germany) and freshly used for experiments without freezing to avoid differentiation. CD34^+^ cells were stimulated for one day in X-Vivo 15 medium (Lonza, Switzerland) supplied with cytokines (100 ng/ml of Flt-3 ligand, 100 ng/ml of SCF, 20 ng/ml of TPO, and 20 ng/ml of IL-6; Peprotech, Rocky Hill, NJ) and 5% penicillin/streptomycin, maintained at a density of 5.10^5^ cells/ml and transduced the day after stimulation with lentiviral vector at a MOI of 100 as previously described ([@bib6]), washed 24 hr later and cultured in X-Vivo 15 medium, 50 ng/ml of Flt-3 ligand, 25 ng/ml of SCF and 20 ng/ml of TPO. MRC5 fibroblasts serum and 5% penicillin/streptomycin. MRC-5 fibroblasts were transduced with a lentivector at a MOI of 10, 3 days before HCMV infection. Monocytes were purified from HCMV seropositive donors buffy coat, obtained at the EFS (Etablissement Français du Sang, France), with CD14^+^ magnetic selection kit (Miltenyi Biotec). After 7 days of HCMV reactivation treatment, non differentiation of cells was controlled by different marker expression by FACS (CD1a, CD14, CD80, CD86) (Invitrogen, Carlsbad, CA). Cells were cultured in RPMI medium (invitrogen) supplemented with 10% FCS and Peni/strep. The mTOR (Torin1 and rapamycin, Selleckchem, Houston, TX) and ATM (KU55933, LuBioscience, Switzerland) inhibitors were used at 0.1 and 10 µM, respectively, added 30 min before infection. The ATM activator (chloroquine, Sigma--Aldrich, St Louis, MO) was used at 20 µM. The recombinant TNF-α (Peprotech) is used at 5 ng/ml.

Mature DC generation {#s4-2}
--------------------

After 10 days of TB40-E infection, CD34^+^ HSC were cultured for 7 days in X-VIVO-15 medium supplemented with GM-CSF (100 ng/ml), TGF-β (0.5 ng/ml), Flt-3 ligand (100 ng/ml), SCF (20 ng/ml) and TNF-α (50 U/ml) (all from peprotech). This treatment leads to generation of immature dendritic cells that will be pushed to maturation with lipopolysaccharide (LPS, 50 ng/ml) treatment during 3 days, as described in ([@bib40]).

Ethics statement {#s4-3}
----------------

Cord blood was obtained after approval of the project by the local ethics committee, commission cantonale d\'ethique de la recherche sur l\'etre humain, as protocol 146/10. When necessary, samples were obtained following informed consent of the participants.

Lentiviral vectors {#s4-4}
------------------

pLKO vectors were purchased from Sigma--Aldrich and the puromycin was replaced by eGFP (pLKO-shKAP1, pLKO-empty, pLKO-scramble). QuickChange II XL Site directed Mutagenesis Kit (Agilent Technologies Santa Clara, CA) was used to mutate KAP1 Serine 824 into Glutamic Acid in a pFUT plasmid containing a human *Kap1* allele modified by nucleotide substitutions to resist to our shRNA. Production and titration of lentiviral vectors was performed as previously described ([@bib5]).

Viruses {#s4-5}
-------

The AD169 (ATCC, Manassas, VA) and TB40-E (a gift from G Herbein, Besançon, France) HCMV strains were used in this study. Virus stocks were generated in MRC5 or HUVEC cells, collecting particles when cytopathic effects were \>90%. Supernatants were clarified of cell debris by centrifugation at 1,500×*g* for 10 min, ultracentrifuged at 100,000×*g* for 30 min at 4°C and stored at −80°C until use. Virus titers were determined by plaque assay on MRC5 cells using standard methods (MEM2X diluted twofold with solution of 1.6% agarose). MRC-5 were infected at a MOI of 1, while CD34^+^ infection were performed at a MOI of 5, 3 days after or 7 days before transduction with lentivectors.

Chromatin immunoprecipitation (ChIP) {#s4-6}
------------------------------------

Chromatin from 10^7^ CD34^+^ was prepared and immunoprecipitated as in ([@bib6]), with KAP1- (Abcam, UK), H3K9me3- (Diagenode, Belgium), SETDB1- (Abcam) mTOR (Abcam) or S^824^ phosphoKAP1- (Abcam) specific antibodies. TB40-E infected CD34^+^ KAP1-ChIPed DNA was sent to sequencing. The 50 bp reads for KAP1 IP and Total Input were mapped to the HCMV genome (TB40-BAC4 GenBank accession EF999921.1) using the bowtie short read aligner version 0.12.7 ([@bib29]) and allowing up to three mismatches over the whole length of the read. The signal of the total input was then subtracted from the KAP1 IP signal using a custom made PERL program (see [Source code 1](#SD3-data){ref-type="supplementary-material"}) and regions with similar signal were merged together. The resulting regions were ranked according to their signal. The signal follows a normal distribution (tested with Shapiro--Wilk normality test) thus we considered as enriched regions the extreme right part of the distribution. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE53271 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53271). SYBR green qPCR was performed to quantify enrichment at specific loci. Total Input Fold enrichment was quantified by the classical following calculation: 100 × 2\^−(CT of ChIPed DNA − CT of Total Input). Cellular promoters regions were used as negative (EVX-1; GAPDH) or positive (ZNF-180; RP11-517P14.7) controls for PCR enrichment. 28 highly enriched peaks were found for the HCMV TB40-E strain, and two negative regions were designed for qPCR controls.

ImmunoFluorescence {#s4-7}
------------------

MRC-5 were cultured directly on coverslips. Around 2 × 10^5^ CD34^+^ were attached to slides by cytospinning with Shandon EZ Single Cytofunnel (Thermo Fisher Scientific, Waltham, MA). Cells were then fixed and permeabilised with Methanol during 5 min at −20°C, and saturated with PBS 5% FCS during 2 hr at room temperature (RT). Primary staining with IE-, anti-S^824^ phopshoKAP1-, KAP1- mTOR (all from Abcam) anti-KAP1 S^473^ phosphoKAP1 (BioLegend, San Diego, CA) specific antibodies was performed in PBS 5% FCS at 4°C overnight or 3 hr at RT, before addition of secondary antibodies (Alexa-488 or -565) in PBS 5% FCS during 1 hr at RT. Dapi bath was performed during 10 min at RT, and slides were mounted with Fluoromount-G (Southern Biotech, Birmingham, AL).

RT-PCR {#s4-8}
------

Cells were sorted for GFP (control of transduction) and CD34 expression. RNA was extracted by Trizol and reverse transcribed with Superscript II (both from Invitrogen) according to the manufacturer\'s instructions. All qPCR were performed with SYBR green mix (Roche, Switzerland). Primers used in this work were designed by Primer Express software (Applied Biosystems) and their sequences are available on [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

Cell fractionation {#s4-9}
------------------

Cells were washed two times with cold PBS and centrifuged. Pellets were resuspended in 500 µl of cytop Buffer (Triton 0.25%, Tris HCl 10 mM, EDTA 5 mM, EGTA 0.5 mM and proteases inhibitor cocktail) and incubated 3--5 min on ice. After centrifugation, supernatant was kept as soluble part (cytoplasm) and pellet were lysed with TNEN 250:0.1 buffer (NaCl 250 mM, Tris HCl 50 mM, EDTA 5 mM, NP40 0.1% and proteases inhibitor cocktail) 20--30 min on ice. After centrifugation, supernatants were kept as insoluble part (nucleus) and pellets were lysed in Urea 8 M, 10 min at 95°C to recover chromatin part. Total amount of protein was quantified by BCA assay.

Western blot analyses {#s4-10}
---------------------

Cells lysates were subjected to SDS/PAGE on 4--12% polyacrylamide gels (Invitrogen). iBlots on Nitrocellulose membrane (Invitrogen) were treated with KAP1- Histone 3- α-Tubulin- (Abcam) mTOR- S6 ribosomal protein- phospho S6 ribosomal protein (Cell Signaling, Beverly, MA) and βactin- (Calbiochem, San Diego, CA) specific antibodies, followed by polyclonal rabbit HRP-conjugated antibody, and protein bands were detected by using an ECL-plus kit (Thermo-Scientific). Anti-KAP1pS824 antibody was produced in rabbits using a KLH-MBS coupled peptide with the following sequence: AcNH-CAG LSS QEL pSGG P-CONH2 from Eurogentec.

In vitro kinase assays {#s4-11}
----------------------

GST-KAP1 and 1 U of mTOR (475987 Millipore, Billerica, MA) were incubated in phosphorylation buffer (25 mM Hepes pH 6.8, 10 mM MgCl~2~, 0.5 mM DTT, 200 μM ATT, 1× Complete protease inhibitor cocktail from Roche, 1% BSA) in a total volume of 15 μl for 30 min with shaking at room temperature. mTOR activity is inhibited with 100 nM of Torin1.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Release of Human Cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switch" for consideration at *eLife*. Your article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor), a guest Reviewing editor, and two additional reviewers.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

*Reviewer 1*:

The manuscript by Rauwel et al. reports that the master co-repressor KAP1 is involved in regulating viral lytic gene expression during latent infection of undifferentiated myeloid cells by HCMV; KAP1 mediates recruitment of chromatin post-translational modifiers to the viral Major Immediate Early Promoter (MIEP) resulting in repression of the viral MIEP and the establishment of a latent transcription programme.

This is an interesting paper which presents data which goes some way to identifying at least one of the mechanisms by which the viral MIEP might be repressed during latent infection of myeloid cells with HCMV. However, in some cases the data could be presented more clearly, proper controls should be used and the data should be analysed in more depth.

The authors should address the following:

1\) [Figure 1](#fig1){ref-type="fig"} provides key data for the authors\' hypothesis but conflate two very different analyses. Panel A and B analyse permissiveness of cells for infection (KAP1 is knocked-down, then cells are infected with HCMV); panel D analyses reactivation (cells are infected with HCMV, left to go latent and then KAP1 is knocked-down); it is unclear from the information in the figure legend how the cells were treated in panel C but my reading of the text suggests that panel C represents virus production from cells which were knocked-down for KAP1 prior to infection.

These different analyses are informative but should be separated clearly into panels which show analyses of permissiveness (KAP1 knock down then HCMV infection) and reactivation from latency (HCMV infection, then subsequent KAP1 knock-down). A key question then is whether cells that are reactivated from latency (HCMV infection, then subsequent KAP1 knock-down) actually produce virus in this model. This only appears to be shown, in panel C, for cells that have been made permissive (KAP1 knock down then HCMV infection). This is important, as delivery genome in the context of virions (with pp71 tegument activator etc.) is a very different condition to reactivation of latent genome (in which no such tegument proteins will be present).

The authors should carry out a comprehensive analysis of IE/E/late RNAs (as shown in panels 1 A/B) on cells that are induced to reactivate by KAP1 depletion (HCMV infection, then subsequent KAP1 knock-down) and also analyse these cells for de novo virus production (as shown in panel C). This is important as more data are accumulating to suggest that other hurdles, besides just induction of IE1/IE2, may be needed for full reactivation of infectious virus.

2\) [Figure 2 and 3](#fig2 fig3){ref-type="fig"}. These analyses should be carried out side-by-side with latent myeloid cells that have been induced to reactivate by standard differentiation conditions (not compared to permissive fibroblasts, or to an laboratory isolate of virus that is missing a large amount of viral genome and is inefficient at establishing latency in CD34^+^ cells).

3\) [Figure 4 and 5](#fig4 fig5){ref-type="fig"}. I am uncertain why the authors have reverted to using permissive fibroblasts for these analyses. They should be carried out in latent CD34^+^ which have been differentiated to reactivate latent HCMV genome (alternatively, latent monocytes differentiated to DCs could be used).

4\) The authors must discuss their observations in the light of recently published data that mTOR inhibition does not prevent HCMV reactivation from dendritic cells ([@bib16]) and that macrophages infected with HCMV, contrary to observations with fibroblasts, are sensitive to rapamycin ([@bib37]). This reinforces the reason why some of the analyses in fibroblasts shown in [Figures 4 and 5](#fig4 fig5){ref-type="fig"} should be carried out in differentiated myeloid cells.

Reviewer 2:

This paper seeks to examine a role for KAP1 in the control of HCMV gene expression during latency and reactivation. The premise is very interesting. The Trono group have performed some fascinating work looking to dissect the role of this protein in the context of endogenous retroviruses but in, this instance, the data does not convince.

A more minor issue is that the use of data in lytic data from infected MRC5 proves confusing and reduces the clarity of the report whereas data in the supplementary pertaining to latent cells should be in the main text to support the authors conclusions.

1\) [Figure 1](#fig1){ref-type="fig"} implies that KAP1 is important for the establishment of latency: KO of KAP1 function results in more IE gene expression. Yet the authors then go on in [Figure 3--figure supplement 1AB](#fig3s1){ref-type="fig"} to study AD169, \'as a model virus that does not establish latency\', and see that KAP1 binds this viral genome just as efficiently as TB40-E in CD34^+^ cells. The argument is that KAP1 exerts functions via recruitment of secondary modulators (HP1 etc.). This, to me, needs to be explored. For instance, a recent report from the Pari laboratory suggests HCMV encodes a viral RNA that recruits Polycomb repressor complex and H3K27meth marks at the MIEP. Why aren\'t HP1 etc. recruited? How does KAP1 effect these functions? This seems pivotal for understanding the role of KAP1. Ultimately, what is it about AD169 that negates any activity of KAP1? An alternative explanation could be that the data from analysing TB40-E and AD169 suggests that KAP1 binding to the viral genome is irrelevant and that any KAP1 effects observed in [Figure 1](#fig1){ref-type="fig"} are indirect due to the multitude effects KAP1 KO would have on other cellular function which then impact on HCMV gene expression.

2\) Which KAP1 (indirect) binding site do the authors believe is important for controlling the MIEP (given that it doesn\'t appear to bind to be recruited directly to the MIEP in [Figure 2](#fig2){ref-type="fig"})? Some means to block KAP1 recruitment to the viral genome (via sequence mutagenesis) would provide more compelling evidence that KAP1 binding to the viral DNA drives heterochromatic formation at the MIEP. However, this would require identification of the KAP1 binding partner tethering it to the viral DNA. I appreciate the siRNA KO of KAP1 blocks heterochromatic formation at the MIEP but the AD169 observation requires explanation and again suggests that any KAP1 effects could be highly indirect and due to major changes in the cellular biology when knocking out such a key regulator. Again the AD169 data really argues against KAP1 binding being important for controlling latency since KAP1 is recruited to this genome perfectly well but does not provide the same level of control as it apparently does in TB40-E.

3\) The authors make an important observation in their studies of CD34^+^ precursors ([Figure 8](#fig8){ref-type="fig"}). The chloroquinone expt (thought to be via KAP1) has only a minor effect on HCMV reactivation and you need subsequent NF-kB stimulation to make it more robust. But they never compare it to DCs directly they just make inference (even DCs given these additional treatments). This would be very interesting and provide a more complete set of data. That aside, is the prediction that if you were to KO KAP1 and see the effect observed in [Figure 1D](#fig1){ref-type="fig"} then the addition of chloroquinone (thought to be active via modulation of KAP1) to KAP1 KO cells should have no incremental impact on HCMV reactivation if the authors predictions are true i.e. if KAP1 mediated repression is deleted by siRNA then any effects of chloroquinone should be abrogated.

In summary, the link between KAP1, heterochromatic control of viral latency and the activation of mTOR pathways is all correlative. I think there has, at least, to be some appreciation that whilst pharmacological modulators of KAP1 could trigger reactivation the data does not state it is the activity of those inhibitors towards KAP1 which is mediating the effect. One would presume ATM promotes phosphorylation of a number of cellular proteins but that does not mean they are all involved in HCMV reactivation. The paper sets out to show that KAP1 is the regulator of HCMV latency and reactivation and becomes less and less convincing. If the premise of the paper was chloroquinone and ATM trigger HCMV reactivation and we aim to identify a mechanism it would be more compelling.

Reviewer 3:

The authors provide evidence that shKAP1 transduction can induce high levels of hCMV transcription and virus production in latently infected CD34^+^ cells, but not in permissively infected MRC-5 cells. They show by ChIP-Seq and ChIP-PCR that KAP1 binds to some locations of the HCMV genome in CD34^+^ cells. ChIP with KAP pS824-specific antibody suggests that phosphorylated KAP is enriched in MRC-5 cells, but not CD34^+^ cells. They show that chloroquine treatment induces HCMV reactivation from CD34^+^ cells, and that this is attenuated by treatment with an ATM inhibitor, but not an inhibitor of mTOR. They also show that addition of TNF augments chloroquine activation of HCMV transcription and viral production in CD34^+^ cells. The authors conclude that HCMV latency is regulated by ATM or mTOR phosphorylation of KAP1 S824.

This is an interesting paper, with many intriguing findings covering a great breadth of phenomena that control HCMV latency and reactivation. However, while there is evidence for each claim, the evidence is often minimal and without sufficient controls to rule out alternative explanations. Some of the experimental data (especially the imaging data) is lacking critical controls and quantification. Without deeper analysis of each of the many conclusions, the manuscript appears superficial and the conclusions are not strongly justified.

Specific comments:

1\) [Figure 2A](#fig2){ref-type="fig"}, ChIP-Seq: the statistics of the ChIP-Seq should be provided. How many total reads, how many reads mapped back to the CMV genome. Also, the peak calling algorithm is not entirely clear. What is the quality of the ChIP-Seq on cellular genome (this should be relatively simple to provide and will serve as quality control for the ChIP-Seq experiment). Also, the methods for normalization of the ChIP-Seq and ChIP-PCR ([Figure 3](#fig3){ref-type="fig"}) are not clearly described.

2\) What sequence specific DNA binding proteins on the viral genome recruit KAP? Are there any characterized KRAB Zn finger proteins at each of these KAP bound sites?

3\) [Figure 3C](#fig3){ref-type="fig"}: While the absolute values of pS824 KAP binding in CD34 cells are low, they are at similar levels relative to the CD34 KAP binding observed for the MRC-5. In other words, the observed percentage of pS^824^KAP in CD34 (10:2) and MRC-5 (40:8) relative to total KAP are identical.

4\) [Figure 4](#fig4){ref-type="fig"} requires some statistical/quantitative analysis- how representative are these images?

5\) [Figure 5C](#fig5){ref-type="fig"}, mTOR ChIP assays: it is untypical for a kinase-like mTOR to remain associated with its substrate and viral chromatin. Is there any evidence that mTOR remains stably associated with KAP by coIP experiment?

6\) [Figure 5, IE](#fig5){ref-type="fig"}: is not very convincing or clear as to what is colocalized and where. It is also not clear what stage of infection is presented for each virus, and how typical this is of CMV infection.

7\) What is the timing of mTOR recruitment to the HCMV genome during reactivation? If it is recruited to the replication compartments, than it must be recruited very late in the process after early gene transcription. How does this fit with the model the mTOR may be regulating KAP control of viral transcription and reactivation.

8\) The effects of chloroquine on HCMV viral production is impressive, but chloroquine has many pleiotropic effects on the cell and it is not clear that KAP is a major regulator under these conditions. One way to demonstrate the importance of the KAP pS^824^ in control of HCMV would be to re-introduce the KAP wt or KAP S^824^A into shKAP depleted cells and assay HCMV reactivation. A mutation like S^824^A can be assayed for its ability to block KAP phosphorylation and viral reactivation.

9\) The different effects of TORIN and KU on HCMV are interesting, but may not fit well with the overall model of a KAP1 phospho-switch. The effects of these inhibitors on KAP pS^824^ needs to be assessed by Western blot during normal infection and reactivation induced by chloroquine.

10.7554/eLife.06068.035

Author response

Reviewer 1:

*\[...\] The authors should address the following*:

*1)* [*Figure 1*](#fig1){ref-type="fig"} *provides key data for the authors\' hypothesis but conflate two very different analyses. Panel A and B analyse permissiveness of cells for infection (KAP1 is knocked-down, then cells are infected with HCMV); panel D analyses reactivation (cells are infected with HCMV, left to go latent and then KAP1 is knocked-down); it is unclear from the information in the figure legend how the cells were treated in panel C but my reading of the text suggests that panel C represents virus production from cells which were knocked-down for KAP1 prior to infection*.

The [Figure 1](#fig1){ref-type="fig"} legend was complemented, we effectively forgot to mention that panel C represents virus production from cells depleted for KAP1 prior to infection and that it completes results exhibited in panel B.

*These different analyses are informative but should be separated clearly into panels which show analyses of permissiveness (KAP1 knock down then HCMV infection) and reactivation from latency (HCMV infection, then subsequent KAP1 knock-down). A key question then is whether cells that are reactivated from latency (HCMV infection, then subsequent KAP1 knock-down) actually produce virus in this model. This only appears to be shown, in panel C, for cells that have been made permissive (KAP1 knock down then HCMV infection). This is important, as delivery genome in the context of virions (with pp71 tegument activator etc.) is a very different condition to reactivation of latent genome (in which no such tegument proteins will be present)*.

*The authors should carry out a comprehensive analysis of IE/E/late RNAs (as shown in panels 1 A/B) on cells that are induced to reactivate by KAP1 depletion (HCMV infection, then subsequent KAP1 knock-down) and also analyse these cells for de novo virus production (as shown in panel C). This is important as more data are accumulating to suggest that other hurdles, besides just induction of IE1/IE2, may be needed for full reactivation of infectious virus*.

The new [Figure 1D-E](#fig1){ref-type="fig"} provides a complete analysis of IE/E/L HCMV RNA levels in cells that are induced to reactivate the virus by KAP1 depletion as requested. It also demonstrates that viral activation, which can only be expected to be partial owing to the persistence of some KAP1 in the cells, can be boosted by combining the KAP1 knockdown with TNF-α mediated- NF-κB activation.

*2)* [*Figure 2 and 3*](#fig2 fig3){ref-type="fig"}*. These analyses should be carried out side-by-side with latent myeloid cells that have been induced to reactivate by standard differentiation conditions (not compared to permissive fibroblasts, or to an laboratory isolate of virus that is missing a large amount of viral genome and is inefficient at establishing latency in CD34*^*+*^ *cells)*.

We had chosen the MRC-5 model to provide a clear comparison between latency and full-blown viral replication. Now we followed the reviewer's excellent suggestion to monitor HCMV reactivation when latently infected CD34 cells are induced to differentiate into mature dendritic cells (mDC). We thus performed KAP1-, pS^824^KAP-, SetDB1-, H3K9Me3- and HP1α-specific ChIPs in infected CD34^+^-derived- mDCs (New [Figure 3](#fig3){ref-type="fig"} and [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}) and transferred the corresponding MRC-5 data to [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}. The new data nicely confirm that, in HCMV-replicating mDCs, it is the pS^824^ of KAP1 that is associated with the viral genome, which is correspondingly devoid of SETDB1 and H3K9me3.

*3)* [*Figure 4 and 5*](#fig4 fig5){ref-type="fig"}*. I am uncertain why the authors have reverted to using permissive fibroblasts for these analyses. They should be carried out in latent CD34*^*+*^ *which have been differentiated to reactivate latent HCMV genome (alternatively, latent monocytes differentiated to DCs could be used)*.

We performed the IF studies in fibroblast because these cells are far more amenable to this type of analysis than mDCs due both to their higher rates of infection and to their adherent status. Since mDCs and MRC5 cells are comparable in terms of the HCMV recruitment of KAP1 subspecies, SETDB1 and H3K9me3 (see new [Figure 3](#fig3){ref-type="fig"}), we think that this is fair.

*4) The authors must discuss their observations in the light of recently published data that mTOR inhibition does not prevent HCMV reactivation from dendritic cells (*[@bib16]*) and that macrophages infected with HCMV, contrary to observations with fibroblasts, are sensitive to rapamycin (*[@bib37]*). This reinforces the reason why some of the analyses in fibroblasts shown in* [*Figures 4 and 5*](#fig4 fig5){ref-type="fig"} *should be carried out in differentiated myeloid cells*.

The Discussion was modified to include a sentence on the recently published Glover et al.'s paper. The fact that rapamycin has no effect on in vitro HCMV reactivation in dendritic cells could be explained by the addition of the drug to immature cells, where we could already observe low levels of viral expression, suggesting that KAP1 is already at least partly phosphorylated in this setting. Which may be different in monocytes/macrophages, where mTOR seems accordingly be more important. Exploring these other settings, both from an epigenetic standpoint and regarding possible effects of mTOR on later steps of viral replication, is beyond the scope of this manuscript.

Reviewer 2:

*This paper seeks to examine a role for KAP1 in the control of HCMV gene expression during latency and reactivation. The premise is very interesting. The Trono group have performed some fascinating work looking to dissect the role of this protein in the context of endogenous retroviruses but in, this instance, the data does not convince*.

*A more minor issue is that the use of data in lytic data from infected MRC5 proves confusing and reduces the clarity of the report whereas data in the supplementary pertaining to latent cells should be in the main text to support the authors conclusions*.

*1)* [*Figure 1*](#fig1){ref-type="fig"} *implies that KAP1 is important for the establishment of latency: KO of KAP1 function results in more IE gene expression. Yet the authors then go on in* [*Figure 3--figure supplement 1AB*](#fig3s1){ref-type="fig"} *to study AD169, \'as a model virus that does not establish latency\', and see that KAP1 binds this viral genome just as efficiently as TB40-E in CD34*^*+*^ *cells. The argument is that KAP1 exerts functions via recruitment of secondary modulators (HP1 etc.). This, to me, needs to be explored. For instance, a recent report from the Pari laboratory suggests HCMV encodes a viral RNA that recruits Polycomb repressor complex and H3K27meth marks at the MIEP. Why aren\'t HP1 etc. recruited? How does KAP1 effect these functions? This seems pivotal for understanding the role of KAP1. Ultimately, what is it about AD169 that negates any activity of KAP1? An alternative explanation could be that the data from analysing TB40-E and AD169 suggests that KAP1 binding to the viral genome is irrelevant and that any KAP1 effects observed in* [*Figure 1*](#fig1){ref-type="fig"} *are indirect due to the multitude effects KAP1 KO would have on other cellular function which then impact on HCMV gene expression*.

Our data, whether illustrated in the first version of our manuscript or added since then (see new [Figures 1 and 3](#fig1 fig3){ref-type="fig"}), fully support a model whereby KAP1 is associated with the HCMV genome in both latently and productively infected cells, but differentially impacts on viral gene expression according to its S^824^ phosphorylation status, which is explained by the inhibitory effect of this post-translational modification on the secondary recruitment of HP1 and SETDB1, hence on the deposition of repressive marks including H3K9me3. Why viral strains such as AD169 fail to enter latency in CD34 cells is an interesting issue, which is discussed in our manuscript, but the experimental exploration of which is beyond the scope of this study.

*2) Which KAP1 (indirect) binding site do the authors believe is important for controlling the MIEP (given that it doesn\'t appear to bind to be recruited directly to the MIEP in* [*Figure 2*](#fig2){ref-type="fig"}*)? Some means to block KAP1 recruitment to the viral genome (via sequence mutagenesis) would provide more compelling evidence that KAP1 binding to the viral DNA drives heterochromatic formation at the MIEP. However, this would require identification of the KAP1 binding partner tethering it to the viral DNA. I appreciate the siRNA KO of KAP1 blocks heterochromatic formation at the MIEP but the AD169 observation requires explanation and again suggests that any KAP1 effects could be highly indirect and due to major changes in the cellular biology when knocking out such a key regulator. Again the AD169 data really argues against KAP1 binding being important for controlling latency since KAP1 is recruited to this genome perfectly well but does not provide the same level of control as it apparently does in TB40-E*.

We previously demonstrated that heterochromatin can spread tens of kilobases away from a primary genomic KAP1 recruiting site ([@bib20], reference 31 herein). Here, we demonstrate that it also true in the HCMV episome, with both H3K9me3 and HP1 extending to the MIEP in spite of the absence of direct KAP1 binding at this locus.

Blocking KAP1 recruitment via mutagenesis would require the fine mapping of KAP1 recruiting site and their deletion or mutation, which for close to 30 such sites detected on the HCMV genome is not only daunting but unlikely to be possible without profoundly perturbing other features essential to the virus.

For AD169-related comments, see above.

*3) The authors make an important observation in their studies of CD34*^*+*^ *precursors (*[*Figure 8*](#fig8){ref-type="fig"}*). The chloroquinone expt (thought to be via KAP1) has only a minor effect on HCMV reactivation and you need subsequent NF-kB stimulation to make it more robust. But they never compare it to DCs directly they just make inference (even DCs given these additional treatments). This would be very interesting and provide a more complete set of data. That aside, is the prediction that if you were to KO KAP1 and see the effect observed in* [*Figure 1D*](#fig1){ref-type="fig"} *then the addition of chloroquinone (thought to be active via modulation of KAP1) to KAP1 KO cells should have no incremental impact on HCMV reactivation if the authors predictions are true i.e. if KAP1 mediated repression is deleted by siRNA then any effects of chloroquinone should be abrogated*.

In response to the reviewer's excellent suggestion, we performed pharmacological reactivation on KAP1 KD CD34^+^ cells whether or not complemented with wild-type KAP1 or with the non-phosphorylatable KAP1 S824A mutant (new [Figure 6--figure supplement6](#fig6s6){ref-type="fig"}). We observed that chloroquine had no additional impact on the levels of HCMV reactivation induced by KAP1 depletion, and that it could reactivate the virus in KD cells rescued with wild type but not S^824^A KAP1. It strongly supports a model whereby chloroquine de-represses HCMV gene expression through KAP1 phosphorylation, as expected from its ability to activate ATM.

*In summary, the link between KAP1, heterochromatic control of viral latency and the activation of mTOR pathways is all correlative. I think there has, at least, to be some appreciation that whilst pharmacological modulators of KAP1 could trigger reactivation the data does not state it is the activity of those inhibitors towards KAP1 which is mediating the effect. One would presume ATM promotes phosphorylation of a number of cellular proteins but that does not mean they are all involved in HCMV reactivation. The paper sets out to show that KAP1 is the regulator of HCMV latency and reactivation and becomes less and less convincing. If the premise of the paper was chloroquinone and ATM trigger HCMV reactivation and we aim to identify a mechanism it would be more compelling*.

Reviewer 3:

*\[...\] This is an interesting paper, with many intriguing findings covering a great breadth of phenomena that control HCMV latency and reactivation. However, while there is evidence for each claim, the evidence is often minimal and without sufficient controls to rule out alternative explanations. Some of the experimental data (especially the imaging data) is lacking critical controls and quantification. Without deeper analysis of each of the many conclusions, the manuscript appears superficial and the conclusions are not strongly justified*.

*Specific comments*:

*1)* [*Figure 2A*](#fig2){ref-type="fig"}*, ChIP-Seq: the statistics of the ChIP-Seq should be provided. How many total reads, how many reads mapped back to the CMV genome. Also, the peak calling algorithm is not entirely clear. What is the quality of the ChIP-Seq on cellular genome (this should be relatively simple to provide and will serve as quality control for the ChIP-Seq experiment). Also, the methods for normalization of the ChIP-Seq and ChIP-PCR (*[*Figure 3*](#fig3){ref-type="fig"}*) are not clearly described*.

All statistics and Datasets of the ChIP-Seq will be available on Geo as described in Material and methods. We had 163 Million total reads and mapped 135 Million of them on the human genome. Besides this, 400,000 reads corresponded to the HCMV genome. As the CMV-specific signal was broad, the MACS software was not appropriate for peak calling, requesting the development of a special algorithm. All positive, poorly enriched and negative regions were also analyzed by qPCR, which confirmed the results of the ChIP-Seq. The method of ChIP-PCR normalization is explained in the Material and methods section. The Quality control for the ChIP-seq is provided in [Author response image 1](#fig9){ref-type="fig"}, together with its Total Input Quality control in [Author response image 2](#fig10){ref-type="fig"}:10.7554/eLife.06068.036Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.036](10.7554/eLife.06068.036)10.7554/eLife.06068.037Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.037](10.7554/eLife.06068.037)

Examples of positive peaks on the cellular genome as additional quality controls for the experiment are shown in [Author response image 3](#fig11){ref-type="fig"}, [Author response image 4](#fig12){ref-type="fig"}, and [Author response image 5](#fig13){ref-type="fig"}:10.7554/eLife.06068.038Author response image 3.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.038](10.7554/eLife.06068.038)10.7554/eLife.06068.039Author response image 4.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.039](10.7554/eLife.06068.039)10.7554/eLife.06068.040Author response image 5.**DOI:** [http://dx.doi.org/10.7554/eLife.06068.040](10.7554/eLife.06068.040)

2\) What sequence specific DNA binding proteins on the viral genome recruit KAP? Are there any characterized KRAB Zn finger proteins at each of these KAP bound sites?

Good questions... At this stage, we do not know. It may indeed be that KAP1 is recruited by KRAB-ZNF proteins. This is consistent with the failure of an RBCC-deleted KAP1 mutant to associate with the HCMV genome, as the RBCC domain of KAP1 is what recognizes KRAB-ZNFs, but this domain can also mediate other types of protein-protein interactions.

*3)* [*Figure 3C*](#fig3){ref-type="fig"}*: While the absolute values of pS824 KAP binding in CD34 cells are low, they are at similar levels relative to the CD34 KAP binding observed for the MRC-5. In other words, the observed percentage of pS*^*824*^*KAP in CD34 (10:2) and MRC-5 (40:8) relative to total KAP are identical*.

It is impossible to compare levels of enrichment obtained by performing ChIP with 2 different antibodies in 2 different cell models. Nevertheless, we observed that with KAP1-specific antibody, which is able to precipitate the phosphorylated and non-phosphorylated forms, there are regions of the HCMV genome that score negative (depicted as HCMV Neg1 and HCMV Neg 2). The pS824 KAP1-specific ChIPs gave positive results on the 28 peaks scored positive with the KAP1-specific antibody, but also did not detect a signal at these neg1 and neg2 regions in mDC or MRC-5 fibroblasts, but scored globally negative in latently infected CD34^+^, which provides the necessary controls.

*4)* [*Figure 4*](#fig4){ref-type="fig"} *requires some statistical/quantitative analysis- how representative are these images?*

Even though only 3 or 4 cells are illustrated on the picture, we analyzed a large number of them (several tens) to make sure that we were not misled by non-representative occurrences.

*5)* [*Figure 5C*](#fig5){ref-type="fig"}*, mTOR ChIP assays: it is untypical for a kinase-like mTOR to remain associated with its substrate and viral chromatin. Is there any evidence that mTOR remains stably associated with KAP by coIP experiment?*

The genomic recruitment of a kinase was previously described in the context of MSK1-HP1γ complexes (Harouz H, et al., Embo J., 2014, Nov 18;33(22):2606-22) and also with KAP1-MSK1 (our lab : Singh K. et al., Genes and Dev., 2015, in press). We do not have evidence that mTOR is stably associated with KAP1, and we do not expect it to be the case: instead, we think that the kinase is only recruited to HCMV-bound KAP1 molecules, as suggested by the finding that the kinase is still able to repress a genomic target in HCMV-infected cells. Of note, the ChIP protocol most likely "fixes" an interaction that might otherwise be not so stable.

*6)* [*Figure 5, IE*](#fig5){ref-type="fig"}*: is not very convincing or clear as to what is colocalized and where. It is also not clear what stage of infection is presented for each virus, and how typical this is of CMV infection*.

We do not claim colocalization of IE and mTOR. We are just illustrating (with help of white arrows) that, in infected cells (expressing IE) some mTOR-positive foci can be detected in the nucleus whereas in uninfected the mTOR signal diffuse and cytoplasmic.

*7) What is the timing of mTOR recruitment to the HCMV genome during reactivation? If it is recruited to the replication compartments, than it must be recruited very late in the process after early gene transcription. How does this fit with the model the mTOR may be regulating KAP control of viral transcription and reactivation*.

We agree with the reviewer that, according to our findings, it is the recruitment of mTOR or some other KAP1-targeting kinase at least to some HCMV-bound KAP1 molecules that jumpstarts viral gene expression by relieving heterochromatic marks. As such, it cannot be defined as happening in "viral replication compartments", because it precedes viral replication. We modified the corresponding statement in the discussion. Fine monitoring of the timing of mTOR recruitment in a system where HCMV naturally exits from latency to induce productive infection would be worthwhile, but it is not straightforward, hence beyond the scope of the present study.

*8) The effects of chloroquine on HCMV viral production is impressive, but chloroquine has many pleiotropic effects on the cell and it is not clear that KAP is a major regulator under these conditions. One way to demonstrate the importance of the KAP pS*^*824*^ *in control of HCMV would be to re-introduce the KAP wt or KAP S*^*824*^*A into shKAP depleted cells and assay HCMV reactivation. A mutation like S*^*824*^*A can be assayed for its ability to block KAP phosphorylation and viral reactivation*.

*Very good suggestions, which helped strengthen out model through additional experiments illustrated in new* [*Figure 6--figure supplement 6*](#fig6s6){ref-type="fig"} *as explained in our response to reviewer 1, point 3*.

*9) The different effects of TORIN and KU on HCMV are interesting, but may not fit well with the overall model of a KAP1 phospho-switch. The effects of these inhibitors on KAP pS*^*824*^ *needs to be assessed by Western blot during normal infection and reactivation induced by chloroquine*.

The effect of Torin and KU on KAP1 phosphorylation was documented by IF in the MRC-5 model, as depicted in [*Figure 4*](#fig4){ref-type="fig"} and [*Figure 4--figure supplement 1*](#fig4s1){ref-type="fig"}. The corresponding antibody works poorly for Western blot, and monitoring KAP1 phosphorylation during viral reactivation in low numbers of HCMV-infected cells is beyond our current technical abilities.
